October 1, 2016 03:03 AM EDT
R&D

J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

John Carroll

Editor & Founder

J&J has long had high hopes for its an­ti-in­flam­ma­to­ry IL-23 drug guselkum­ab. And to­day in Vi­en­na they de­tailed the first round of Phase III da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times